Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q ...
Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré ...
Annexon releases topline data for phase 2 GA study
Annexon Virtual R&D Day: Guillain-Barré Syndrome – A Focus on the ...
Annexon Biosciences - Poretta & Orr, Inc.
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care ...
Annexon Spotlights GA Phase III, GBS Regulatory Plans and ANX1502 ...
Annexon presents Phase 3 data on tanruprubart for GBS | Annexon ...
Annexon Biosciences on LinkedIn: Annexon broadens autoimmune franchise ...
Annexon Biosciences - LifeScienceHistory.com
Brazil. 02nd Jan, 2023. In this photo illustration, the Annexon logo is ...
Annexon Biosciences on LinkedIn: Geographic atrophy (GA) is the leading ...
Annexon Biosciences on LinkedIn: Today we announced our fourth quarter ...
#scripawards #gbs | Annexon Biosciences
Annexon Biosciences on LinkedIn: #geographicatrophy #aao2024 #eyecelerator
Annexon Biosciences on LinkedIn: #guillainbarrésyndrome #pns24
Annexon (ANNX) Stock Analysis: Insider Buying & Phase 3 Catalysts ...
Annexon Releases Q4 2025 Financial Results and Portfolio Updates ...
Annexon (ANNX) Investor Presentation - Slideshow (NASDAQ:ANNX ...
Annexon Biosciences on LinkedIn: #autoimmune #neurodegenerative # ...
Annexon Biosciences on LinkedIn: Today we released our second quarter ...
#icymi | Annexon Biosciences
#ga | Annexon Biosciences
Annexon Biosciences on LinkedIn: #guillainbarrésyndrome
Annexon Biosciences - Huntington's Disease Society of AmericaHuntington ...
Annexon Presents at 2026 AAN Meeting on Tanrubart in Guillain-Barré ...
Annexon Biosciences Presentation_Dec 2025.pdf
Annexon Biosciences: Pioneering a New Era in Geographic Atrophy ...
Annexon Biosciences - AnnualReports.com
Annexon Biosciences on LinkedIn: Today, we announced the closing of a ...
#pns24 | Annexon Biosciences
Annexon Drops after Geographic Atrophy Candidate Disappoints - TipRanks.com
Annexon Biosciences on LinkedIn: #rarediseaseday #raredisease # ...
Annexon Inc. (ANNX): Ready to Break Through in Neuroinflammatory ...
Annexon In-Person and Virtual KOL Event to Discuss Vonaprument for the ...
Annexon Biosciences on LinkedIn: #arvo24 #geographicatrophy
Annexon Biosciences Careers | Levels.fyi
Annexon details neuroinflammation drug pipeline | ANNX Annual Report (10-K)
Annexon Biosciences - AnnualReports.co.uk
Annexon Biosciences on LinkedIn: #eha2022 #waiha
#c1q | Annexon Biosciences
Annexon Biosciences: A Neuroinflammatory Breakthrough on the Horizon
Annexon Shares Surge on Bullish Analyst Sentiment - Stocks Today
Annexon - 10-K annual report 2025
#icymi #rwe #gbs | Annexon Biosciences
Annexon Biosciences on LinkedIn: #hd #huntingtonsdisease # ...
#gbs #patients | Annexon Biosciences
#autoimmune #neurodegenerative #ophthalmologic | Annexon Biosciences
#rwe #gbs | Annexon Biosciences | 10 comments
Annexon Biosciences on ANX005 for Guillain-Barré syndrome | Exigyn ...
Annexon Balanced Scorecard: 4 Benefits, 6 Drawbacks
Congratulations, Douglas Love and Annexon Biosciences! | William Carson
Annexon Aktie: Explosiver Analysten-Optimismus!
#media #gbs | Annexon Biosciences
Science - Annexon Biosciences
Annexon Biosciences on LinkedIn: #jpm23
#geographicatrophy | Annexon Biosciences
I’m excited to join the amazing team at Annexon Biosciences. Thanks for ...
Annexon Biosciences on LinkedIn: #cowenhealthcare
Annexon Induces Growth with New Employee Grants in Biotech - Investors ...
Annexon Biosciences Highlights Strategy at TD Cowen Event
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones ...
PESTLE Analysis of Annexon – PortersFiveForce.com
Annexon closes $100M round! - Engine Room
ANNX | Annexon Announces Pricing of $125 Million Underwritten Public ...
#guillainbarrésyndrome #pns24 | Annexon Biosciences
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data ...
#gbs | Annexon Biosciences
아넥슨 (ANNX) 바이오사이언스 Annexon Bioscience 미국 바이오 길랑바레증후군 치료제 관련주
Annexon Biosciences to Present at the 44th Annual J.P. Morgan ...
#gbs #ga | Annexon Biosciences
page_title
A Pivotal Year Ahead for Annexon’s Clinical Ambitions
Annexon, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Annexon生物科技將於全球醫療會議上發表新療法進展 - ss future
临床阶段生物制药公司：Annexon, Inc.(ANNX) | 美股之家 - 港股美股开户投资百科全书
Annexon的C1q抗体抑制剂缘何获得4400万美元？
治疗抑郁症、渐冻症...2024上半年这5项临床试验值得关注
Contact Us - Medicine Unfolded
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS ...
Portfolio | Bain Capital Life Sciences
Annexon, Inc. (ANNX) 🧠💊 Biotech with Massive Upside, FDA Near Term ...
三季度11款值得关注的抗体药医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
2023年5月：4项临床失败案例，肾病、眼病、非小细胞肺癌！_摩熵医药(原药融云)
Role and Rationale for Classical Complement Inhibition - Retina Today
Annexon(ANNX.US)盘前暴涨超55%ANX0053期临床试验达主要终点 |快报_凤凰网视频_凤凰网
ANNX Q4 2025 Earnings Report on 3/30/2026
Annexon's Q2 2026 Cash Runway Sets Up High-Risk, High-Conviction ...
(ANX-007) - 药物靶点：C1q_在研适应症：年龄相关性黄斑变性，地图样萎缩_专利_临床_研发
Annexon, Inc. Common Stock (ANNX) Stock Price Today: $5.94
Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic ...
Annexon, Inc. - PRISM MarketView
Neurocritical Care Society
